Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Currently Recruiting

  • Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering

    This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

    This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

    Eligible Tumour Type(s): Acute Myeloid Leukemia (AML)
    Sponsor: In-House
    Principal Investigator: Dr. Mark Minden
    NCT#: NCT02483312

    https://clinicaltrials.gov/ct2/show/NCT02483312
  • Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)
    Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Fallopian Tube Tumours, Malignant Pleural Mesothelioma, Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma of the Oral Cavity, Triple Negative Breast Cancer
    Sponsor: In-house
    Principal Investigator: Drs. Lillian Siu & Anna Spreafico (Second PI)
    NCT#: NCT03686202

    https://clinicaltrials.gov/ct2/show/NCT03686202
  • Prospective Analysis of INteStinal Microbiome and Autoimmune PanEls as PrediCtors of Toxicity in Phase I ImmunOncology Patients (INSPECT-IO)
    Eligible Tumour Type(s): Solid Cancer
    Sponsor: In-house
    Principal Investigator: Dr. Anna Spreafico
    NCT#: NCT04107311

    https://clinicaltrials.gov/ct2/show/study/NCT04107311
  • LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (LANDMARC)
    Eligible Tumour Type(s): Epstein-Barr virus- and human papillomavirus -related cancers, Hepatocellular carcinoma
    Sponsor: In-house
    Principal Investigator: Dr. Kathy Han
    NCT#: NCT04665388

    https://clinicaltrials.gov/ct2/show/NCT04665388
  • ADP-0000-001

    Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

    Eligible Tumour Type(s): Hematological Malignancies, Solid Cancer
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT02636855

    https://clinicaltrials.gov/ct2/show/NCT02636855
  • ADP-0055-001

    A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors

    Eligible Tumour Type(s): Esophageal Cancer, Esophagogastric Junction Disorder, Gastric Cancer, Head and Neck, Non-small Cell Lung Cancer, Urothelial Carcinoma
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT04044859

    https://clinicaltrials.gov/ct2/show/NCT04044859
  • ADP-0044-002

    A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

    Eligible Tumour Type(s): Sarcoma
    Principal Investigator: Dr. Albiruni Razak
    NCT#: NCT04044768

    https://clinicaltrials.gov/ct2/show/NCT04044768
  • IOV-COM-202

    A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

    Eligible Tumour Type(s): Metastatic Melanoma, Non-small Cell Lung Cancer
    Principal Investigator: Dr. Adrian Sacher
    NCT#: NCT03645928

    https://clinicaltrials.gov/ct2/show/NCT03645928
  • IMCnyeso-101

    A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer 

    Eligible Tumour Type(s): Solid Cancer
    Principal Investigator: Dr. Marcus Butler
    NCT#: NCT03515551

    https://clinicaltrials.gov/ct2/show/NCT03515551
  • GSK208467

    Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) 

    Eligible Tumour Type(s): Sarcoma
    Principal Investigator: Dr. Albiruni Razak
    NCT#: NCT03967223

    https://clinicaltrials.gov/ct2/show/NCT03967223

Pages